Revolution Medicines, Inc. RVMD
We take great care to ensure that the data presented and summarized in this overview for Revolution Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVMD
View all-
Vanguard Group Inc Valley Forge, PA14.8MShares$582 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.7MShares$580 Million0.09% of portfolio
-
Black Rock Inc. New York, NY12.3MShares$485 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY7.55MShares$298 Million3.08% of portfolio
-
Farallon Capital Management LLC San Francisco, CA7.51MShares$296 Million1.13% of portfolio
-
Nextech Invest Ag6.3MShares$248 Million37.95% of portfolio
-
Bvf Inc San Francisco, CA5.98MShares$236 Million5.77% of portfolio
-
Casdin Capital, LLC New York, NY5.62MShares$221 Million14.62% of portfolio
-
State Street Corp Boston, MA5.39MShares$212 Million0.01% of portfolio
-
Alphabet Inc. Mountain View, CA5.3MShares$209 Million7.58% of portfolio
Latest Institutional Activity in RVMD
Top Purchases
Top Sells
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Insider Transactions at RVMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 03
2024
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.93%
|
$400,000
$40.03 P/Share
|
May 03
2024
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.2%
|
$20,000
$2.68 P/Share
|
Apr 10
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Indirect |
10,000
-14.11%
|
$350,000
$35.34 P/Share
|
Apr 10
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
7,500
-1.63%
|
$262,500
$35.48 P/Share
|
Apr 10
2024
|
Sushil Patel |
SELL
Open market or private sale
|
Direct |
2,155
-12.07%
|
$79,735
$37.0 P/Share
|
Apr 10
2024
|
Sushil Patel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,155
+10.77%
|
$34,480
$16.8 P/Share
|
Mar 27
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,500
-1.35%
|
$45,000
$30.95 P/Share
|
Mar 18
2024
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,914
-2.05%
|
$90,334
$31.58 P/Share
|
Mar 18
2024
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
2,123
-0.78%
|
$65,813
$31.58 P/Share
|
Mar 18
2024
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,252
-2.19%
|
$38,812
$31.58 P/Share
|
Mar 18
2024
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,261
-1.22%
|
$39,091
$31.58 P/Share
|
Mar 18
2024
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
5,788
-1.24%
|
$179,428
$31.58 P/Share
|
Mar 12
2024
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,936
-5.28%
|
$269,824
$34.07 P/Share
|
Mar 12
2024
|
Margaret A Horn Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,936
+5.01%
|
$31,744
$4.09 P/Share
|
Mar 11
2024
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,735
-9.95%
|
$534,990
$34.02 P/Share
|
Mar 11
2024
|
Margaret A Horn Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,735
+9.05%
|
$62,940
$4.09 P/Share
|
Mar 01
2024
|
Mark A Goldsmith |
SELL
Grant, award, or other acquisition
|
Direct |
90,000
-16.18%
|
-
|
Mar 01
2024
|
Margaret A Horn Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+22.35%
|
-
|
Mar 01
2024
|
Xiaolin Wang |
BUY
Grant, award, or other acquisition
|
Direct |
24,200
+22.26%
|
-
|
Mar 01
2024
|
Jack Anders Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,400
+20.37%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 3.84M shares |
---|---|
Exercise of conversion of derivative security | 223K shares |
Grant, award, or other acquisition | 90K shares |
---|---|
Open market or private sale | 343K shares |